FIN 211
Alternative Names: FIN-211Latest Information Update: 17 Nov 2022
At a glance
- Originator Finch Therapeutics Group
- Class Bacteria; Behavioural disorder therapies
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pervasive child development disorders
Most Recent Events
- 01 Sep 2022 Finch Therapeutics suspended the initiation of phase Ib AUSPIRE trial in pervasive child development disorders (autism spectrum disorder) and gastrointestinal symptoms in the US
- 16 May 2022 Finch Therapeutics announces intention to submit an IND application for Pervasive child development disorders in the fourth quarter of 2022
- 31 Mar 2022 Finch Therapeutics plans the phase Ib AUSPIRE trial for Pervasive child development disorders and Gastrointestinal symptoms (In children) in third quarter of 2022